中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2011, Vol. 46 Issue (23) :1855-1856    DOI:
��ҩ���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
���������ٰ���ҩ�����׻��ᰬ�ղ���
�¾������Ӵ䣬����������С��*
�й�ҽѧ��ѧԺ-����Э��ҽѧԺ����Э��ҽԺҩ���ƣ�������100730

Download: PDF (352KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ 
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� ���������ٰ�     
Abstract��
Keywords��   
�ո�����: 2011-11-11;
���ñ���:   
.���������ٰ���ҩ�����׻��ᰬ�ղ���[J]  �й�ҩѧ��־, 2011,V46(23): 1855-1856
.[J]  Chinese Pharmaceutical Journal, 2011,V46(23): 1855-1856
��
[1] FDA. Label approved on 11/15/2010 for HALAVEN, NDA no. 201532[EB/OL]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf.[2] Twelves C, Cortes J, Vahdat L T, et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer[J]. Clin Breast Cancer, 2010,10(2):160-163.[3] JENNIFER A S, LESLIE W, OLGA AZARENKO, et al. Eribulin Binds at Microtubule Ends to a Single Site on Tubulin to Suppress Dynamic Instability[J]. Biochem�� 2010, 49(6): 1331�C1337.[4] JAVIER C, ALBERTO J M, STEFAN G. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer[J]. Cancer Treat Rev, 2011, 22��10����1-12.
û���ҵ������������
Copyright 2010 by �й�ҩѧ��־